Abstract
Background
Estrogen might protect women against gastric adenocarcinoma of the intestinal histological type. We addressed this hypothesis and proposed that gastric estrogen receptors (ERs) are involved.
Methods
A population-based cohort of patients with gastric adenocarcinoma diagnosed in 1958–2004 in the county of Stockholm was identified through the Swedish Cancer Register. The patients were categorized regarding their endogenous estrogen exposure at diagnosis into: women aged less than 50 years, labelled “exposed women” (n = 364), men aged less than 50 years, labelled “unexposed men” (n = 396), and women aged more than 70 years, labelled “unexposed women” (n = 3008). Tumor specimens were reviewed, and 289 cases were classified into intestinal (n = 101) or diffuse type (n = 188). Cases of intestinal adenocarcinomas (n = 45) were tested for presence of ERalpha, ERbeta, and ERbeta cx by immunohistochemistry.
Results
Compared to “exposed women”, the intestinal type of gastric adenocarcinoma was more than four times more common among “unexposed men” (odds ratio [OR], 4.7; 95% confidence interval [CI], 2.2–10.3) and nine times more common among “unexposed women” (OR, 9.1; 95% CI, 4.3–19.6). No differences in ER expression were found. A comparison of ERs in tissues taken from the tumors and adjacent gastric mucosa revealed a loss of ERbeta and a gain of ERalpha in the tumor cells. The presence of ERbeta cx was identified for the first time in gastric tumors.
Conclusion
Gastric adenocarcinoma of the intestinal type is less common in women with high endogenous estrogen exposure, indicating a preventive effect of estrogen. No differences in the distribution of ERs was found between the three estrogen exposure groups. The presence of ERbeta cx in gastric cancer warrants further investigation.
Article PDF
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002;5:213–219.
Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 2006;95:118–122.
Lindblad M, Garcia Rodriguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006;94:136–141.
Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev 2004;13:2203–2207.
Frise S, Kreiger N, Gallinger S, Tomlinson G, Cotterchio M. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the Canadian National Enhanced Cancer Surveillance System. Ann Epidemiol 2006;16:908–916.
Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986;231:1150–1154.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925–5930.
Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002;128:319–324.
Tokunaga A, Kojima N, Andoh T, Matsukura N, Yoshiyasu M, Tanaka N, et al. Hormone receptors in gastric cancer. Eur J Cancer Clin Oncol 1983;19:687–689.
Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998;247:75–78.
Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999;91:786–790.
Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 1977;39:2475–2485.
Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004;10:2421–2428.
Wang HH, Mangano MM, Antonioli DA. Evaluation of T-lymphocytes in esophageal mucosal biopsies. Mod Pathol 1994;7:55–58.
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905–931.
Matsui M, Kojima O, Uehara Y, Takahashi T. Characterization of estrogen receptor in human gastric cancer. Cancer 1991;68:305–308.
Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 2007;67:3955–3962.
Hansson LR, Engstrand L, Nyren O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995;109:885–888.
Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007;102:1789–1798.
Ye W, Ekstrom AM, Hansson LE, Bergstrom R, Nyren O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer 1999;83:223–229.
Lunet N, Valbuena C, Vieira AL, Lopes C, Lopes C, David L, et al. Fruit and vegetable consumption and gastric cancer by location and histological type: case-control and meta-analysis. Eur J Cancer Prev 2007;16:312–327.
Ekstrom AM, Eriksson M, Hansson LE, Lindgren A, Signorello LB, Nyren O, et al. Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res 1999;59:5932–5937.
Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudice G, Westert GP, et al. Socioeconomic position and the risk of gastric and oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Epidemiol 2007;36:66–76.
Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408–412.
Freedman ND, Chow WH, Gao YT, Shu XO, Ji BT, Yang G, et al. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut 2007;56:1671–1677.
Inoue M, Ito LS, Tajima K, Yamamura Y, Kodera Y, Takezaki T, et al. Height, weight, menstrual and reproductive factors and risk of gastric cancer among Japanese postmenopausal women: analysis by subsite and histologic subtype. Int J Cancer 2002;97:833–838.
Kaneko S, Tamakoshi A, Ohno Y, Mizoue T, Yoshimura T. Menstrual and reproductive factors and the mortality risk of gastric cancer in Japanese menopausal females. Cancer Causes Control 2003;14:53–59.
La Vecchia C, D’Avanzo B, Franceschi S, Negri E, Parazzini F, Decarli A. Menstrual and reproductive factors and gastric-cancer risk in women. Int J Cancer 1994;59:761–764.
Palli D, Cipriani F, Decarli A, Galli M, Saieva C, Fraumeni JF Jr, et al. Reproductive history and gastric cancer among postmenopausal women. Int J Cancer 1994;56:812–815.
Heuch I, Kvale G. Menstrual and reproductive factors and risk of gastric cancer: a Norwegian cohort study. Cancer Causes Control 2000;11:869–874.
Lauren PA, Nevalainen TJ. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high-and low-risk areas. Cancer 1993;71:2926–2933.
Sipponen P, Marshall BJ. Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 2000;29:579–592, v–vi.
Stemmermann GN, Brown C. A survival study of intestinal and diffuse types of gastric carcinoma. Cancer 1974;33:1190–1195.
Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004.
Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574–582.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A 2006;103:2959–2964.
Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer 2003;39:1251–1258.
Kojima O, Takahashi T, Kawakami S, Uehara Y, Matsui M. Localization of estrogen receptors in gastric cancer using immunohistochemical staining of monoclonal antibody. Cancer 1991;67:2401–2406.
Sica V, Nola E, Contieri E, Bova R, Masucci MT, Medici N, et al. Estradiol and progesterone receptors in malignant gastrointestinal tumors. Cancer Res 1984;44:4670–4674.
Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61:2537–2541.
Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001;61:5331–5335.
Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol 2007;33:195–201.
Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in humans. Nucleic Acids Res 1998;26:3505–3512.
Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769–5776.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chandanos, E., Rubio, C.A., Lindblad, M. et al. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer 11, 168–174 (2008). https://doi.org/10.1007/s10120-008-0475-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-008-0475-6